Gerard J. Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University and Director of the Temple Lung Center, recently discussed findings from a secondary analysis of the MATINEE clinical trial. He shared insights with Healio and Medscape during the American Thoracic Society (ATS) International Conference.
The secondary analysis focused on the use of mepolizumab as an add-on treatment to optimal triple therapy for patients with COPD. According to Dr. Criner, this approach “may help prevent severe exacerbations” in these patients.
Dr. Criner’s discussion centered around results from a phase 3 trial that explored this potential benefit for individuals suffering from COPD.
